CeGaT’s Genetic Tumor Diagnostics portfolio supports cancer care by providing molecular information for diagnosis, therapy selection and monitoring. Services cover hereditary tumor syndromes as well as somatic tumor analyses, including CancerPrecision®, CancerEssential®, CancerFusionRx®, CancerIFP, CancerNeo®, CancerDetect®, CancerMRD and CancerAdvice®. Depending on the clinical question and available sample material, analyses can help detect cancer predispositions, identify disease mechanisms, evaluate planned therapies, detect fusion transcripts, analyse the tumor microenvironment, identify neoantigens or monitor minimal residual disease and recurrence. The goal is to provide physicians with actionable molecular insights that support precise, timely and patient-specific treatment decisions throughout the patient journey and disease course.